$TG Therapeutics(TGTX)$ $Spdr S&P Biotech Etf(XBI)$ $iShares Biotechnology ETF(IBB)$ $SPDR S&P 500 ETF Trust(SPY)$ Aside from probably one or two Big Pharma names that likely can't get involved because of antitrust concerns, what's still most underappreciated is Briumvi's patent protection out to 2042, with very little biosimilar threat on the horizon.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
